Portfolio
Twelve investments at the frontier of machine intelligence, neuromorphic hardware, and advanced AI systems. Every company we back is pushing the boundaries of what is technically possible.
Portfolio Companies
NeuralDrive
Full-stack autonomous navigation AI platform for industrial and logistics environments, integrating onboard neuromorphic inference with cloud-based fleet intelligence and continuous learning pipelines.
NeuralDrive's continuous learning architecture — which improves navigation policy from every operational hour across its fleet — creates a compounding moat that pure hardware competitors cannot replicate. Their 500,000 sq ft of live warehouse operations at seed stage is exceptional commercial traction.
DeepSense
Multimodal perception platform combining radar, lidar, and vision with proprietary transformer architectures for real-time environmental understanding in autonomous systems and industrial robotics.
DeepSense's multimodal fusion architecture outperformed every incumbent solution in industrial anomaly detection benchmarks. Their 7-facility deployment track record before the seed round told us the technology was production-ready — not a laboratory demonstration.
QuantumMesh
Distributed quantum networking platform delivering entanglement-based secure communication channels for enterprise and government applications, with a fully operational pilot in three US metropolitan areas.
QuantumMesh's founders demonstrated operational QKD latency under 8ms — a threshold that makes quantum-secure communication practical for real-time financial and defense applications. Their government relationships and three-city metro deployment gave us confidence in both technical maturity and procurement pipeline.
PharmaFlow AI
Drug discovery acceleration platform using generative AI and active learning to identify novel therapeutic targets from multi-omics data, cutting target identification timelines from years to weeks.
PharmaFlow AI's active learning loop — which continuously prioritizes the most informative experiments based on accumulated biological data — represents a fundamentally better approach to hypothesis generation than high-throughput screening. Their two top-20 pharma partnerships validate both the science and the commercial model.
Pitch Neuron Factory
We are actively seeking seed-stage deep-tech AI companies. If you are building at the frontier of machine intelligence, we want to hear from you.
What We Look For
Technically differentiated teams with genuine research depth, defensible intellectual property, and a clear path from laboratory breakthrough to commercial product.
Check Size
We lead pre-seed and seed rounds with initial checks of $500K to $1.5M, with meaningful reserves for follow-on investments through Series A.
Our Process
Founder meeting, technical deep-dive, reference checks, and investment decision within four to six weeks. No black boxes, no committee theater.